Published in J Virol on March 01, 1985
Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing). J Virol (1988) 3.84
Monoclonal antibody cure and prophylaxis of lethal Sindbis virus encephalitis in mice. J Virol (1986) 1.43
Antibody inhibits defined stages in the pathogenesis of reovirus serotype 3 infection of the central nervous system. J Exp Med (1989) 1.41
A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. Vaccine (2011) 1.39
Antibody-induced restriction of viral gene expression in measles encephalitis in rats. J Virol (1990) 1.36
Recent mumps outbreaks in vaccinated populations: no evidence of immune escape. J Virol (2011) 1.18
Clearance of a persistent paramyxovirus infection is mediated by cellular immune responses but not by serum-neutralizing antibody. J Virol (1990) 1.17
Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health. Emerg Infect Dis (2014) 1.16
Intracellular maturation of mumps virus hemagglutinin-neuraminidase glycoprotein: conformational changes detected with monoclonal antibodies. J Virol (1986) 0.99
Immunoglobulin class and immunoglobulin G subclass enzyme-linked immunosorbent assays compared with microneutralization assay for serodiagnosis of mumps infection and determination of immunity. J Clin Microbiol (1987) 0.97
Monoclonal antibodies against the fusion protein are protective in necrotizing mumps meningoencephalitis. J Virol (1986) 0.96
Estimates of mumps seroprevalence may be influenced by antibody specificity and serologic method. Clin Vaccine Immunol (2013) 0.89
Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months. Virol J (2013) 0.86
Cross-neutralization between three mumps viruses & mapping of haemagglutinin-neuraminidase (HN) epitopes. Indian J Med Res (2016) 0.79
Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol (1981) 14.45
Biological activities of immunoglobulins of different classes and subclasses. Adv Immunol (1974) 5.22
On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice. J Immunol (1983) 3.57
Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2. Infect Immun (1982) 3.02
Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis. Nature (1982) 2.64
Murine hepatitis virus-4 (strain JHM)-induced neurologic disease is modulated in vivo by monoclonal antibody. Virology (1984) 2.57
Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease. Infect Immun (1981) 2.49
Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo. J Virol (1984) 2.05
The effects of monoclonal antibodies on biologic activities of structural proteins of Sendai virus. J Immunol (1982) 1.94
Use of monoclonal antibodies for analysis of antibody-dependent immunity to ocular herpes simplex virus type 1 infection. Infect Immun (1982) 1.92
Hydrocephalus following viral infection: the pathology of aqueductal stenosis developing after experimental mumps virus infection. J Neuropathol Exp Neurol (1968) 1.75
Determination of the protective epitopes on the glycoproteins of Venezuelan equine encephalomyelitis virus by passive transfer of monoclonal antibodies. J Immunol (1982) 1.60
Elucidation of the topography and determination of the protective epitopes on the E glycoprotein of Saint Louis encephalitis virus by passive transfer with monoclonal antibodies. J Immunol (1984) 1.58
A topological and functional model of epitopes on the structural glycoprotein of tick-borne encephalitis virus defined by monoclonal antibodies. Virology (1983) 1.53
Immunochemical identification of rubella virus hemagglutinin. Virology (1983) 1.44
Evaluation of survival in challenge experiments. Microbiol Rev (1978) 1.42
Neutralizing and non-neutralizing monoclonal antibodies to the E2 glycoprotein of Semliki Forest virus can protect mice from lethal encephalitis. J Gen Virol (1983) 1.40
Induction of subacute murine measles encephalitis by monoclonal antibody to virus haemagglutinin. Nature (1981) 1.30
Polypeptides of mumps virus. J Virol (1976) 1.09
Breakdown of the blood--cerebrospinal fluid barrier to immunoglobulin in mice injected intracerebrally with a neurotropic influenza A virus. Post-exposure treatment with monoclonal antibody promotes recovery. J Neuroimmunol (1981) 1.07
The reactions of monoclonal antibodies with structural proteins of mumps virus. J Immunol (1984) 1.07
Comparative studies of five strains of mumps virus in vitro and in neonatal hamsters: evaluation of growth, cytopathogenicity, and neurovirulence. J Med Virol (1980) 1.05
Ultrastructure of mumps virus replication in newborn hamster central nervous system. Lab Invest (1974) 1.04
Immunological properties of purified mumps virus glycoproteins. J Gen Virol (1978) 1.00
Differentiation of mumps virus strains with monoclonal antibody to the HN glycoprotein. Infect Immun (1982) 0.98
A comparison of the structural polypeptides of five strains of mumps virus. J Gen Virol (1980) 0.98
The polypeptides of mumps virus and their synthesis in infected chick embryo cells. Virology (1981) 0.98
Study of protein characteristics that influence entry into the cerebrospinal fluid of normal mice and mice with encephalitis. J Clin Invest (1982) 0.96
Natural pathogenicity of mumps virus for suckling hamsters on intracerebral inoculation. J Immunol (1953) 0.92
Passive protection of mice and sheep against bluetongue virus by a neutralizing monoclonal antibody. Infect Immun (1983) 0.91
Persistence of neuroadapted mumps virus in brains of newborn hamsters after intraperitoneal inoculation. J Infect Dis (1976) 0.89
Mumps virus-induced hydrocephalus in hamsters. Ultrastructure of the chronic infection. Lab Invest (1977) 0.88
Biosynthesis of mumps virus F glycoprotein: non-fusing strains efficiently cleave the F glycoprotein precursor. J Gen Virol (1983) 0.88
Immunochemical features of a case of progressive rubella panencephalitis. Clin Exp Immunol (1982) 0.87
Data on the efficiency of specific antimumps immunoglobulins in the prevention of mumps and of its complications. Virologie (1980) 0.81
Polypeptide composition of mumps virus. Med Microbiol Immunol (1977) 0.81
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
In situ hybridization histochemistry of Ca2+/calmodulin-dependent protein kinase in developing rat brain. J Neurosci (1990) 3.00
Slow virus replication: the role of macrophages in the persistence and expression of visna viruses of sheep and goats. J Gen Virol (1982) 2.87
An essential role for postsynaptic calmodulin and protein kinase activity in long-term potentiation. Nature (1989) 2.83
Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc Natl Acad Sci U S A (1989) 2.10
Improved identification of intracortical lesions in multiple sclerosis with phase-sensitive inversion recovery in combination with fast double inversion recovery MR imaging. AJNR Am J Neuroradiol (2007) 1.83
H reflex studies in cerebral palsy patients undergoing partial dorsal rhizotomy. Muscle Nerve (1994) 1.83
Sequence similarities between human immunodeficiency virus gp41 and paramyxovirus fusion proteins. AIDS Res Hum Retroviruses (1987) 1.82
Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol (2006) 1.78
Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology (2001) 1.76
Three-dimensional reconstructions of calcium/calmodulin-dependent (CaM) kinase IIalpha and truncated CaM kinase IIalpha reveal a unique organization for its structural core and functional domains. J Biol Chem (2000) 1.70
Herpes zoster ophthalmicus and delayed contralateral hemiparesis caused by cerebral angiitis: diagnosis and management approaches. Ann Neurol (1983) 1.60
Variable results after rituximab in neuromyelitis optica. J Neurol Sci (2012) 1.58
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology (2000) 1.52
Measles encephalomyelitis--clinical and immunologic studies. N Engl J Med (1984) 1.50
The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology (2009) 1.49
Copolymer 1: a most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability. Neurology (1995) 1.48
Acquired toxoplasmosis. A neglected cause of treatable nervous system disease. Arch Neurol (1975) 1.44
Immunochemical identification of rubella virus hemagglutinin. Virology (1983) 1.44
Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis. Arch Neurol (2001) 1.40
3D MPRAGE improves classification of cortical lesions in multiple sclerosis. Mult Scler (2008) 1.39
A peptide model for calmodulin trapping by calcium/calmodulin-dependent protein kinase II. J Biol Chem (1996) 1.38
The relationship of MS to physical trauma and psychological stress: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (1999) 1.38
Sequence determination of the mumps virus HN gene. Virology (1988) 1.38
Effects of seasons on magnetic resonance imaging--measured disease activity in patients with multiple sclerosis. Ann Neurol (2001) 1.35
Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand (2010) 1.34
Neutralizing antibody spectrum determines the antigenic profiles of emerging mutants of visna virus. Infect Immun (1981) 1.31
The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology (1999) 1.31
Primary culture of capillary endothelium from rat brain. In Vitro (1981) 1.30
Ca(2+)/calmodulin-dependent protein kinases. Cell Mol Life Sci (2008) 1.30
MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology (2006) 1.29
Progressive rubella panencephalitis. Late onset after congenital rubella. N Engl J Med (1975) 1.28
Conversion of nonfusing mumps virus infections to fusing infections by selective proteolysis of the HN glycoprotein. Virology (1983) 1.28
Biochemical features of mumps virus neuraminidases and their relationship with pathogenicity. Virology (1981) 1.27
Detailed immunologic analysis of the structural polypeptides of rubella virus using monoclonal antibodies. Virology (1985) 1.26
Neuronal and oligodendroglial infection by the WW strain of Theiler's virus. Lab Invest (1979) 1.25
A dual approach for minimizing false lesion classifications on magnetic resonance images. Magn Reson Med (1997) 1.24
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler (2000) 1.23
Cloning and sequencing of the mumps virus fusion protein gene. Virology (1987) 1.20
A fusing mumps virus variant selected from a nonfusing parent with the neuraminidase inhibitor 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology (1986) 1.18
Virus-specific intracytoplasmic inclusions in mouse brain produced by a newly isolated strain of Theiler virus. I. Virologic and morphologic studies. Lab Invest (1977) 1.18
Isolation of metabolically active capillaries from rat brain. J Neurochem (1975) 1.15
A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler (2006) 1.15
Comparison of the arginine esteropeptidases associated with the nerve and epidermal growth factor. J Biol Chem (1976) 1.13
Determinants of overall quality of life in secondary progressive MS: a longitudinal study. Neurology (2001) 1.13
Postinfectious leukoencephalitis complicating Mycoplasma pneumoniae infection. Arch Neurol (1983) 1.12
Nerve growth factor. Adv Protein Chem (1977) 1.12
Neuronal activity increases the phosphorylation of the transcription factor cAMP response element-binding protein (CREB) in rat hippocampus and cortex. J Biol Chem (1996) 1.11
Interactions of FLT-1 and KDR with phospholipase C gamma: identification of the phosphotyrosine binding sites. Biochem Biophys Res Commun (1997) 1.11
Adenine arabinoside in the treatment of progressive multifocal leukoencephalopathy: use of virus-containing cells in the urine to assess response to therapy. Ann Neurol (1977) 1.10
Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology (2004) 1.09
Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain (2001) 1.08
Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol (1998) 1.08
Nerve growth factor (first of three parts). N Engl J Med (1977) 1.07
Identification of domains essential for the assembly of calcium/calmodulin-dependent protein kinase II holoenzymes. J Biol Chem (1998) 1.06
Skeletal muscle CaMKII enriches in nuclei and phosphorylates myogenic factor SRF at multiple sites. Biochem Biophys Res Commun (2000) 1.05
Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial. Neurology (2012) 1.05
Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol (1998) 1.04
Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses. Mult Scler (2008) 1.04
Prognosis of the individual course of disease--steps in developing a decision support tool for Multiple Sclerosis. BMC Med Inform Decis Mak (2007) 1.04
Ultrastructure of mumps virus replication in newborn hamster central nervous system. Lab Invest (1974) 1.04
The neuropathology of progressive rubella panencephalitis of late onset. Brain (1976) 1.04
Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. Neurology (1996) 1.04
Treatment of chronic relapsing inflammatory polyradiculoneuropathy by plasma exchange. Ann Neurol (1979) 1.03
Interaction of the Flt-1 tyrosine kinase receptor with the p85 subunit of phosphatidylinositol 3-kinase. Mapping of a novel site involved in binding. J Biol Chem (1995) 1.03
Characterization of immune complexes in progressive rubella panencephalitis. Ann Neurol (1981) 1.02
Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging. Mult Scler (2001) 1.02
A model of the structural organization of rubella virions. Rev Infect Dis (1985) 1.01
Ischemia-induced translocation of Ca2+/calmodulin-dependent protein kinase II: potential role in neuronal damage. J Neurochem (1992) 0.99
Inactivation and self-association of Ca2+/calmodulin-dependent protein kinase II during autophosphorylation. J Biol Chem (1996) 0.99
Intracellular maturation of mumps virus hemagglutinin-neuraminidase glycoprotein: conformational changes detected with monoclonal antibodies. J Virol (1986) 0.99
Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol (1998) 0.98
Differentiation of mumps virus strains with monoclonal antibody to the HN glycoprotein. Infect Immun (1982) 0.98
Virulence and persistence of three prototype strains of mumps virus in newborn hamsters. Arch Virol (1978) 0.98
EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. Eur J Neurol (2006) 0.97
Composite MRI scores improve correlation with EDSS in multiple sclerosis. Mult Scler (2010) 0.96
Varicella-zoster virus infection of human brain cells and ganglion cells in tissue culture. Arch Virol (1978) 0.96
Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand (2005) 0.96
Active site-directed inhibition of Ca2+/calmodulin-dependent protein kinase type II by a bifunctional calmodulin-binding peptide. Proc Natl Acad Sci U S A (1988) 0.95
Progressive rubella panencephalitis. Arch Neurol (1976) 0.95
Modification of the epidermal growth factor affecting the stability of its high molecular weight complex. J Biol Chem (1976) 0.94
Activation of the alternative complement pathway by mumps infected cells: relationship to viral neuraminidase activity. Arch Virol (1986) 0.94
Light scattering and transmission electron microscopy studies reveal a mechanism for calcium/calmodulin-dependent protein kinase II self-association. J Neurochem (2001) 0.93
Diagnostic tests in normal pressure hydrocephalus. Neurology (1973) 0.93
Rubella-specific immune complexes after congenital infection and vaccination. Infect Immun (1982) 0.93
Experimental panencephalitis induced in suckling mice, by parainfluenza type 1 (6/94) virus, II. Virologic studies. J Neuropathol Exp Neurol (1976) 0.93